Tetracaine is an ester derivative used as a local anesthetic
molecule.
In this study, a series of novel Tetracaine derivatives bearing hydrazide-hydrazone
moiety were designed, synthesized, and evaluated for anticancer activity.
The structures of these compounds were characterized by spectral (1H NMR,13C NMR, FT-IR, and HRMS analyses) methods.
All synthesized compounds were screened for anticancer activity against
two different human cancer cell lines (Colo-205 and HepG2). Among
the synthesized molecules, compounds 2f and 2m showed the most potent anticancer activity against the Colo-205
cell line (IC50 = 50.0 and 20.5 μM, respectively).
Compounds 2k, 2p, and 2s demonstrated
the best anticancer activity against the HepG2 cell line (IC50 = 30.5, 35.9, and 20.8 μM, respectively). mRNA transcription
levels of Bax and caspase-3 genes were determined by real-time polymerase
chain reaction (qRT-PCR) analysis of both Colo-205 and HepG2 cell
lines. Doxorubicin was used as a positive sensitivity reference standard.
qRT-PCR analysis showed that there was a time-dependent rise in the
expression levels of Bax and Caspase 3 on apoptosis. Inhibition of
apoptotic proteins PI3K, Akt, PTEN, pPTEN, FoXO1, FoXO3a, TXNIP, and
p27 was investigated in Colo-205 and HepG2 cells treated with compounds 2f, 2m, 2k, 2p, and 2s by using Western blotting.